Dermatologists need to be more visible in treating chronic spontaneous urticaria (CSU), says Dr. Adam Friedman, co-chair of the ODAC Dermatology, Aesthetic & Surgical Conference. Next Steps in Derm, in partnership with ODAC, interviewed Dr. Friedman, who shared what to consider when approaching a hive or hive-like patient. Hear the burden that patients with CSU face. Find out the first-line treatment for CSU. (Surprise: It’s not oral prednisone.) Watch as Dr. Friedman outlines second- and third-line treatment options for patients who aren’t yet clear. Plus hear why more therapies on the horizon should make dermatology clinicians excited about getting their CSU patients to 100% clearance.
Further Reading
If you want to read more about chronic spontaneous urticaria, check out the following articles published in the Journal of Drugs in Dermatology:
Drugs in Development for Chronic Spontaneous Urticaria
ABSTRACT
Chronic spontaneous urticaria (CSU) is a debilitating disease for which many patients are inadequately treated. However, recent advancements in our understanding of the disease pathophysiology allow us to develop therapies that are more effective for CSU. It may be possible in the future to select personalized treatments based on a patient’s autoimmune endotype. This paper reviews current knowledge on CSU pathogenesis and treatment. It also reviews data for drugs being developed for the treatment of CSU, as listed on ClinicalTrials.gov.
An Updated Therapeutic Strategy for Chronic Idiopathic Urticaria
ABSTRACT
Urticaria, for greater than 6 weeks in the absence of a consistent, identifiable trigger, is termed chronic spontaneous urticaria (CSU). Although the disease course is mostly self-limiting, CSU persists in 20% of patients for more than 5 years, can be debilitating to quality-of-life (QoL), and has been associated with increased anxiety and depression. This review provides a step-by-step approach to treatment from recently updated guidelines and summarizes the latest evidence for off-label options.
Did you enjoy this video interview? Find more here.
